Harmony Biosciences Holdings Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Harmony Biosciences Holdings, Inc. (HRMY) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income145.49128.85181.4734.60-36.94
Depreciation & Amortization24.1124.3623.3921.0810.24
Deferred Income Tax-29.30-13.42-85.940.000.00
Stock Based Compensation42.6031.7126.1715.664.69
Change in Working Capital-7.3235.04-4.110.63-11.63
Change in Accounts Receivable-8.89-19.40-19.90-12.67-17.92
Change in Inventory-1.84-1.070.14-0.61-2.74
Change in Accounts Payable-5.388.952.79-1.56-3.80
Change in Other Working Capital8.795.803.9215.4612.83
Other Operating Activities-27.105.803.9216.1126.25
Net Cash from Operating Activities219.82219.39144.4798.56-2.99
Investing Activities
Capital Expenditures-1.15-0.31-0.170.300.00
Acquisitions-33.07-36.970.000.000.00
Purchases of Investments-6.76-127.47-110.730.000.00
Sales/Maturities of Investments-26.50118.319.07-100.00-2.00
Other Investing Activities-26.500.00-40.00-100.00-2.00
Net Cash from Investing Activities-67.48-46.44-141.83-100.30-2.00
Financing Activities
Debt Repayment-15.00-201.25-2.00-9.65-5.80
Common Stock Issued6.505.068.8430.00147.93
Common Stock Repurchased-2.50-100.000.000.00-0.18
Other Financing Activities-2.50-9.360.00-22.00-36.04
Net Cash from Financing Activities-11.00-105.556.847.42209.16
Summary
Net Change in Cash141.3467.409.485.68204.17
Cash at Beginning of Period311.93244.53235.06229.3825.21
Cash at End of Period453.27311.93244.53235.06229.38
Free Cash Flow218.67219.08144.2998.26-2.99
Supplemental Disclosures
Interest Paid17.3220.0516.3619.8326.20
Income Taxes Paid79.6448.2312.652.880.00